← Leaderboards
Kavita Dhodapkar
Rockefeller University
$7,009,080
Attributed
$10,587,975
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,587,975 · 8
By mechanism
R01$6,664,047 · 4
K12$2,128,138 · 1
P01$1,162,934 · 1
K08$630,720 · 1
M01$2,136 · 1
Top collaborators
- Ignacio E. Sanz9 shared
- Suresh S Ramalingam4 shared
- Kelly C Goldsmith2 shared
Most similar at Rockefeller University
Same institution · by research overlap
- Jeffrey Victor Ravetch$66,226,718
- James G Krueger$4,444,811
- Madhav V Dhodapkar$18,788,265
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsTumorImmuneT-LymphocyteImmunityMalignant NeoplasmsResearch PersonnelAutoimmunityGenomicsPathway InteractionsIn VitroResponseB-LymphocytesEvaluationCell PhysiologyPhenotypeLeadAntigen-Presenting CellsT-Cell ActivationBaseMediatingEnvironmentAnti-Ctla4Frequencies
Grant awards (29)
Tumor and host immune signatures associated with patient outcomes to GD2 chemoimmunotherapy in neuroblastoma$568,722
R01 · FY2025 · CA
Tumor and Host Immune signatures associated with health disparities in outcomes following GD2 immunotherapy in neuroblastoma$576,659
R01 · FY2024 · CA
Core 2$362,923
P01 · FY2024 · CA · contact PI
Emory Clinical Oncology Career Development Award K12 Program$553,731
K12 · FY2023 · CA
B cells in autoimmunity following checkpoint blockade therapy$440,314
R01 · FY2023 · CA · contact PI
B cell depletion to prevent autoimmunity$393,969
R01 · FY2023 · AR · contact PI
Core 2$373,592
P01 · FY2023 · CA · contact PI
Emory Clinical Oncology Career Development Award K12 Program$583,777
K12 · FY2022 · CA
B cells in autoimmunity following checkpoint blockade therapy$445,267
R01 · FY2022 · CA · contact PI
Core 2$426,419
P01 · FY2022 · CA · contact PI
B cell depletion to prevent autoimmunity$397,099
R01 · FY2022 · AR · contact PI
Emory Clinical Oncology Career Development Award K12 Program$635,715
K12 · FY2021 · CA
B cells in autoimmunity following checkpoint blockade therapy$465,730
R01 · FY2021 · CA · contact PI
B cell depletion to prevent autoimmunity$396,705
R01 · FY2021 · AR · contact PI
B cells in autoimmunity following checkpoint blockade therapy$465,726
R01 · FY2020 · CA · contact PI
B cell depletion to prevent autoimmunity$411,840
R01 · FY2020 · AR · contact PI
Emory Clinical Oncology Career Development Award K12 Program$354,915
K12 · FY2020 · CA
B cells in autoimmunity following checkpoint blockade therapy$467,621
R01 · FY2019 · CA · contact PI
Fcgamma mediated regulation of dendritic cell function$405,516
R01 · FY2012 · AI · contact PI
Fcgamma mediated regulation of dendritic cell function$405,516
R01 · FY2011 · AI · contact PI
Fcgamma mediated regulation of dendritic cell function$409,613
R01 · FY2010 · AI · contact PI
Fcgamma mediated regulation of dendritic cell function$413,750
R01 · FY2009 · AI · contact PI
Immune resistance to glioma via dendritic cells$130,464
K08 · FY2008 · AI · contact PI
Immune resistance to glioma via dendritic cells$130,464
K08 · FY2007 · AI · contact PI
Immune resistance to glioma via dendritic cells$130,464
K08 · FY2006 · AI · contact PI
Immune resistance to glioma via dendritic cells$119,664
K08 · FY2005 · AI
ANTITUMOR IMMUNE RESPONSE IN PATIENTS WITH PRIMARY BRAIN TUMORS$330
M01 · FY2005 · RR
Immune resistance to glioma via dendritic cells$119,664
K08 · FY2004 · AI
Antitumor immue response in patients with primary brain tumors$1,806
M01 · FY2004 · RR